Biocon Limited has informed the Exchange about Notification to Stock Exchange

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.3%Reaction day

₹337.75

prior close

₹342.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.9%-0.5% vs market

Pharmaceuticals peers, median of 150sector+0.2%+0.2% vs sector

On the reaction day the stock moved 0.5 pts less than Nifty Midcap 150 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.4

15m

-0.1

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.3+0.9-0.5+0.2+0.2

Next day

+1.2+1.0+0.2+1.1+0.1

-1.4-0.6-0.8+0.2-1.6

+0.8+0.2+0.6+1.0-0.2

-1.3-0.1-1.1+1.2-2.5

-2.0+0.4-2.4+0.7-2.7

-0.8+1.2-2.0+1.4-2.2

15d

-2.4+4.4-6.8+0.8-3.2

+5.7+3.9+1.8+2.1+3.6

+16.9+5.8+11.1+3.8+13.1

+7.7+2.3+5.4-1.0+8.7

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon's wholly owned subsidiary, Biocon Pharma Limited, has received US FDA approval for its ANDA (generic version) of Rivaroxaban Tablets in four strengths: 2.5 mg, 10 mg, 15 mg, and 20 mg. Rivaroxaban is a widely used blood-thinning medication prescribed for treating deep vein thrombosis, pulmonary embolism, and reducing stroke risk in patients with nonvalvular atrial fibrillation. The company stated this approval will further strengthen its portfolio of vertically integrated drug products. No revenue guidance or specific commercial launch timeline was provided in the filing.

Likely market impact

Positive for Biocon — this opens the door to commercialising a generic version of a blockbuster drug (brand name Xarelto) in the large US market, potentially adding to future revenues and reinforcing the company's generic formulations pipeline.